CRISPR Therapeutics AG (CRSP)

In July 2025, the stock trended upwards due to FDA designations and positive Phase 1 clinical trial results, along with a director's share acquisition. In early 2026, CRISPR Therapeutics reported CASGEVY revenue exceeding $100 million in 2025 and outlined strategic priorities for 2026. In late December 2025, the stock fell amid a general market uptick, with analysts forecasting a drop in EPS and revenue. As of January 12, 2026, the stock price was $55.32, a 42.39% increase over the past year.

There is no specific information available indicating demand seasonality for CRISPR Therapeutics AG's products and services. Demand for its therapies is primarily driven by patient need and regulatory approvals rather than seasonal fluctuations.

CRISPR Therapeutics AG is a Swiss-American biotechnology company focused on developing gene-based medicines using its CRISPR/Cas9 gene-editing platform. Their major approved product is CASGEVY, a CRISPR-based therapy for hemoglobinopathies like sickle cell disease and transfusion-dependent beta-thalassemia. The company's pipeline includes programs in hemoglobinopathies, oncology, regenerative medicine, cardiovascular diseases, thromboembolic conditions, and other rare diseases.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with a U.S. subsidiary and R&D operations in Boston (Cambridge) and San Francisco, Massachusetts. It also has business offices in London, United Kingdom, and a manufacturing facility in Framingham, Massachusetts.

CRISPR Therapeutics maintains a strong brand reputation as a leader in gene editing, positively impacted by the approval of CASGEVY and positive clinical trial data. Strategic partnerships with companies like Vertex Pharmaceuticals, Bayer AG, and Sirius Therapeutics also contribute to its strong industry presence. The company navigates the complex regulatory environment and ethical considerations surrounding gene editing, as well as the inherent risks of clinical trials and the competitive biotech industry.

CRISPR Therapeutics AG is heavily dominated by institutional owners, who hold approximately 66% to 76.12% of the company's shares. The top 23 shareholders collectively own 50% of the company. Major institutional owners include ARK Investment Management LLC, BlackRock, Inc., Capital International Investors, Orbis Allan Gray Ltd, State Street Corp, T. Rowe Price Investment Management, Inc., Vanguard Group Inc, UBS Group AG, and Nikko Asset Management Americas, Inc. Individual investors hold approximately 25% to 34% of the company's stock, while insider ownership is under 1%.